Irsogladine improves small-intestinal injuries in regular users of nonsteroidal anti-inflammatory drugs

Gastrointestinal Endoscopy

Volumn 80, Issue 1, 2014, Pages 118-125

  Isomura, Yoshihiro ^a   Yamaji, Yutaka ^a   Yamada, Atsuo ^a   Watanabe, Yoshitaka ^a   Suzuki, Hirobumi ^a   Kobayashi, Yuka ^a   Yoshida, Shuntaro ^a   Watabe, Hirotsugu ^a   Hirata, Yoshihiro ^a   Yoshida, Haruhiko ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; INDOMETACIN; IRSOGLADINE MALEATE; LORNOXICAM; LOXOPROFEN; MOFEZOLAC; NONSTEROID ANTIINFLAMMATORY AGENT; ZALTOPROFEN; ANTIULCER AGENT; IRSOGLADINE; TRIAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CAPSULE ENDOSCOPE; CAPSULE ENDOSCOPY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EROSION; FEMALE; HOSPITAL PATIENT; HUMAN; INTERVENTION STUDY; INTESTINE INJURY; INTESTINE ULCER; MALE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; CHEMICALLY INDUCED; DRUG EFFECTS; INTESTINE MUCOSA; MIDDLE AGED; PATHOLOGY; PEPTIC ULCER; PROSPECTIVE STUDY; SMALL INTESTINE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CAPSULE ENDOSCOPY; FEMALE; HUMANS; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MIDDLE AGED; PEPTIC ULCER; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TRIAZINES;

EID: 84903178000     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2013.12.030     Document Type: Article

References (31)

1. M.C. Allison, A.G. Howatson, and C.J. Torrance et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs N Engl J Med 327 1992 749 754
2. I. Bjarnason, J. Hayllar, and A.J. MacPherson et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans Gastroenterology 104 1993 1832 1847 (Pubitemid 23235480)
3. I. Bjarnason, A.B. Price, and G. Zanelli et al. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures Gastroenterology 94 1988 1070 1074
4. M.J. Langman, L. Morgan, and A. Worrall Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage Br Med J (Clin Res Ed) 290 1985 347 349 (Pubitemid 15115450)
5. D.Y. Graham, A.R. Opekun, and F.F. Willingham et al. Visible small-intestinal mucosal injury in chronic NSAID users Clin Gastroenterol Hepatol 3 2005 55 59 (Pubitemid 40092944)
6. L. Maiden, B. Thjodleifsson, and A. Seigal et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study Clin Gastroenterol Hepatol 5 2007 1040 1045
7. L. Maiden, B. Thjodleifsson, and A. Theodors et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy Gastroenterology 128 2005 1172 1178
8. J.M. Scheiman, N.D. Yeomans, and N.J. Talley et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors Am J Gastroenterol 101 2006 701 710
9. J.L. Goldstein, G.M. Eisen, and B. Lewis et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo Clin Gastroenterol Hepatol 3 2005 133 141 (Pubitemid 40220308)
10. J.L. Wallace, S. Syer, and E. Denou et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis Gastroenterology 141 2011 1314 1322 1322e1-5
11. K. Takeuchi, A. Tanaka, and S. Kato et al. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage Clin Chim Acta 411 2010 459 466
12. K. Higuchi, E. Umegaki, and T. Watanabe et al. Present status and strategy of NSAIDs-induced small bowel injury J Gastroenterol 44 2009 879 888
13. M. Akagi, K. Amagase, and T. Murakami et al. Irsogladine: overview of the mechanisms of mucosal protective and healing- promoting actions in the gastrointestinal tract Curr Pharm Des 19 2013 106 114
14. F. Ueda, K. Ban, and T. Ishima Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor J Pharmacol Exp Ther 274 1995 815 819
15. H. Morita, T. Katsuno, and A. Hoshimoto et al. Connexin 26-mediated gap junctional intercellular communication suppresses paracellular permeability of human intestinal epithelial cell monolayers Exp Cell Res 298 2004 1 8 (Pubitemid 38887301)
16. K. Kamei, Y. Kubo, and N. Kato et al. Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats Dig Dis Sci 53 2008 2657 2666
17. T. Kuramoto, E. Umegaki, and S. Nouda et al. Small intestinal mucosal adaptation in the long-term administration of a NSAID and the efficacy of irsogladine maleate, a gastroprotective drug, and omeprazole in healthy volunteers: a prospective randomized trial Gastrointest Endosc 75 Suppl 2012 257
18. T. Kyoi, M. Oka, and K. Noda et al. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis Life Sci 75 2004 1833 1842 (Pubitemid 39070496)
19. H. Yamamoto, M. Umeda, and H. Mizoguchi et al. Protective effect of Irsogladine on monochloramine induced gastric mucosal lesions in rats: a comparative study with rebamipide World J Gastroenterol 5 1999 477 482
20. H. Morita, T. Katsuno, and A. Hoshimoto et al. Irsogladine, an activator of gap-junctional intercellular communication, suppresses paracellular permeability of human intestinal epithelial cell monolayers through up-regulation of claudin-4 Gastroenterology 130 Suppl 2 2006 A241
21. T. Kyoi, M. Oka, and K. Noda et al. Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats J Pharmacol Sci 93 2003 314 320 (Pubitemid 37521353)
22. M. Sato, N. Manabe, and J. Hata et al. Effect of irsogladine maleate on NSAID-induced reduction of gastric mucosal blood flow in anesthetized dogs Digestion 79 2009 73 78
23. T. Kyoi, K. Noda, and M. Oka et al. Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils Life Sci 76 2004 71 83 (Pubitemid 39389173)
24. D.W. Laird Life cycle of connexins in health and disease Biochem J 394 2006 527 543
25. K.E. Sandoval, and K.A. Witt Blood-brain barrier tight junction permeability and ischemic stroke Neurobiol Dis 32 2008 200 219
26. Y. Takakuwa, Y. Kokai, and K. Sasaki et al. Bile canalicular barrier function and expression of tight-junctional molecules in rat hepatocytes during common bile duct ligation Cell Tissue Res 307 2002 181 189 (Pubitemid 34158530)
27. S. Uzzau, P. Cappuccinelli, and A. Fasano Expression of Vibrio cholerae zonula occludens toxin and analysis of its subcellular localization Microb Pathog 27 1999 377 385 (Pubitemid 30000434)
28. S. Fujimori, T. Seo, and K. Gudis et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy Gastrointest Endosc 69 2009 1339 1346
29. Y. Niwa, M. Nakamura, and N. Ohmiya et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study J Gastroenterol 43 2008 270 276 (Pubitemid 351650037)
30. Y. Nanke, N. Kamatani, and T. Okamoto et al. Irsogladine is effective for recurrent oral ulcers in patients with Behcet's disease: an open-label, single-centre study Drugs R D 9 2008 455 459
31. M. Nomura, M. Kamata, and H. Kojima et al. Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis Ann Oncol 24 2013 1062 1066